Bruce Stuart, PhD
Vice Chair of Research,                                                                   Department of Pharmaceutical Health Services Research                    Executive Director, Peter Lamy Center on Drug Therapy and Aging

Bruce Stuart, PhD, Professor and Executive Director of the Peter Lamy Center on Drug Therapy and Aging is an economist and health services researcher.  He received his economics training at Whitman College and Washington State University.  He began his career in health services research as an economic analyst and later as Director of the Health Research Division in the Michigan Medicaid program in the early 1970s. Leaving state government for academe, Dr. Stuart taught health economics, finance, and research methods at the University of Massachusetts and The Pennsylvania State University.  In 1997 he joined the faculty of the University of Maryland’s School of Pharmacy as the Parke-Davis endowed Chair in Geriatric Pharmacotherapy and was selected as a Maryland Eminent Scholar for his work in geriatric drug use.

Dr. Stuart is an experienced research investigator having directed over 35 grants and contracts with the National Institute on Aging, the Agency for Healthcare Research and Quality, the Centers for Medicare and Medicaid Services, the Assistant Secretary for Planning and Evaluation in DHHS, private foundations, state governments, and private corporations. 

Among his recently completed projects are a study of disease management, formulary design, and other managed care policies on Medicaid recipients with asthma funded by AHRQ, an analysis of cost differences between demented and non-demented nursing home residents for NIA, an analysis of quality indicators for prescription coverage of the elderly for the Commonwealth Fund, and a contract for CMS using MCBS data to evaluate the predictability of prescription drug spending for Medicare beneficiaries and to assess the impact of drug coverage on Medicare Part A and B spending. His current research includes grants from the Commonwealth Fund, the Robert Wood Johnson Foundation, and the Kaiser Family Foundation, all of which focus on policy implications of the new Medicare Part D drug benefit.